Impact of metformin, statin, aspirin and insulin on the prognosis of uHCC patients receiving first line Lenvatinib or Atezolizumab plus Bevacizumab-Reference-Cited by-同舟云学术

Impact of metformin, statin, aspirin and insulin on the prognosis of uHCC patients receiving first line Lenvatinib or Atezolizumab plus Bevacizumab

Published:2024-08-30 Issue:1 Volume:14 Page:
ISSN:2045-2322
Container-title:Scientific Reports
language:en
Short-container-title:Sci Rep

Author:

Rimini Margherita,Montes Margarida,Amadeo Elisabeth,Vitiello Francesco,Kudo Masatoshi,Tada Toshifumi,Suda Goki,Shimose Shigeo,Lonardi Sara,Finkelmeier Fabian,Salani Francesca,Antonuzzo Lorenzo,Marra Fabio,Iavarone Massimo,Cabibbo Giuseppe,Foschi Francesco Giuseppe,Silletta Marianna,Sacco Rodolfo,Rapposelli Ilario Giovanni,Scartozzi Mario,Nicoletta Pella,Aldrighetti Luca,Persano Mara,Camera Silvia,Rossari Federico,Foti Silvia,Kumada Takashi,Hiraoka Atsushi,Iwamoto Hideki,Rizzato Mario Domenico,Himmelsbach Vera,Masi Gianluca,Corradi Mattia,Celsa Ciro,Fabio Conti,Frassineti Giovanni Luca,Cascinu Stefano,Casadei-Gardini Andrea,Presa Jose

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41598-024-70928-z.pdf

Reference24 articles.

1. Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71(3), 209–249. https://doi.org/10.3322/caac.21660 (2021).

2. Finn, R. S. et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N. Engl. J. Med. 382(20), 1894–1905. https://doi.org/10.1056/NEJMoa1915745 (2020).

3. Abou-Alfa, G. K. et al. Phase 3 randomized, open-label, multicenter study of tremelimumab and durvalumab as first-line therapy in patients with unresectable hepatocellular carcinoma: HIMALAYA. J. Clin. Oncol. 40, 379. https://doi.org/10.1200/JCO.2022.40.4_suppl.379- (2022).

4. Pfister, D. et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature 592(7854), 450–456. https://doi.org/10.1038/s41586-021-03362-0 (2021).

5. Rimini, M. et al. Nonalcoholic steatohepatitis in hepatocarcinoma: New insights about its prognostic role in patients treated with Lenvatinib. ESMO Open. 6(6), 100330. https://doi.org/10.1016/j.esmoop.2021.100330 (2021).